



Two key appointments to bolster PharmAust veterinary drug programs

3 October 2017 – Perth, Australia: PharmAust (ASX:PAA), a clinical-stage oncology company, is delighted to announce the first appointments to its veterinary clinical advisory board. Dr Angela Frimberger and Dr Christian Schirvel are international opinion leaders in the field of animal health and will advise and assist PharmAust on its veterinary cancer programme.

These appointments deliver on another key milestone in the company's roadmap released earlier this year. They also mark an important step towards validation and commercialisation of monepantel – PharmAust's lead drug which is currently in clinical development.

Committee Chair: Dr Angela Frimberger V.M.D. Diplomate ACVIM (Oncology)

Dr Frimberger is internationally recognised as a leading veterinary oncologist. Dr Frimberger attended the prestigious University of Pennsylvania Veterinary School in the US where she graduated with a high distinction before specialising in veterinary oncology. She trained as a resident at Tufts University and undertook a research fellowship at University of Massachusetts Cancer Center.

Dr Frimberger is recognised by her peers as an expert in clinical veterinary oncology having led multiple clinical trials, published extensively in peer reviewed journals and text books and is an invited speaker at national and international conferences.

Dr Frimberger is a Co-Director at Veterinary Oncology Consultants. In 2013 she was engaged by PharmAust to oversee the company's veterinary clinical development program.

Dr Frimberger commented "*I am delighted by the invitation to chair PharmAust's clinical advisory board and to contribute to the goal of developing monepantel as a leading drug for treatment of cancer in dogs and humans.*"

Dr Christian Schirvel DVM MSc CAAM

Dr Schirvel was previously Head of Business Development and Licensing (BD&L) at Elanco, one of the world's major animal health companies. Prior to this he served as Global Head BD&L (Therapeutics and Parasiticides) at Novartis Animal Health until it was acquired by Elanco. He was also Global Head of BD&L at Vétoquinol, a top-ten Animal Health Company, and held several senior positions in Global Marketing and Strategic Development at Merial.

Dr Schirvel is a leading global animal health executive with an extensive background in product licensing, corporate strategy, marketing and alliance management. He brings a

wealth of contacts at the highest levels in global animal health companies, which will be of great assistance in PharmAust's business and clinical development activities.

Dr Schirvel commented *"I'm looking forward to working with Angela and the team at PharmAust. Having worked with the company in a previous role, I was impressed with its strategic plans for monepantel, which has the potential to address a significant unmet need in the market."*

PharmAust's CEO Dr Richard Hopkins said *"We are delighted to secure two individuals of this calibre to PharmAust's advisory board. These appointments reaffirm the international interest in our programs and ensure we will receive premium advice to accelerate our drug development and commercialisation strategies."*

We look forward to making further appointments to our advisory board as we continue to engage key opinion leaders with the appropriate clinical and drug development expertise."

Enquiries:

Dr Richard Hopkins
CEO

Tel: 0405 656 868

rhopkins@pharmaust.com

Dr Roger Aston

Executive Chairman

Tel: 0402 762 204

raston@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a contract synthetic drug manufacturer, which generated Aus\$3m in revenues in 2017 at a CAGR of >25%.

PAA's lead drug candidate is Monopantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.